Johnson & Johnson - 63 Year Stock Split History | JNJ
Stock split history for Johnson & Johnson since 1962. Prices shown are actual historical values and are not adjusted for either splits or dividends. Please see the "Historical Prices" tab for adjusted price values.
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $470.415B | $88.821B |
| Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $967.005B | 46.51 |
| AbbVie (ABBV) | United States | $410.546B | 24.58 |
| Roche Holding AG (RHHBY) | Switzerland | $289.653B | 0.00 |
| Novartis AG (NVS) | Switzerland | $278.650B | 14.77 |
| Merck (MRK) | United States | $230.654B | 10.74 |
| Novo Nordisk (NVO) | Denmark | $219.499B | 12.87 |
| Pfizer (PFE) | United States | $146.634B | 8.06 |
| Sanofi (SNY) | France | $128.522B | 12.34 |
| Bayer (BAYRY) | Germany | $33.795B | 5.93 |
| Innoviva (INVA) | United States | $1.660B | 8.31 |